Boundless Bio Appoints New CMO, Elects Director

Ticker: BOLD · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1782303

Boundless Bio, INC. 8-K Filing Summary
FieldDetail
CompanyBoundless Bio, INC. (BOLD)
Form Type8-K
Filed DateAug 20, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001, $3.71, $3.56, $4.10, $16.00
Sentimentneutral

Sentiment: neutral

Topics: executive-appointment, board-election, compensation

TL;DR

Boundless Bio brings in a new CMO and adds a director to the board.

AI Summary

Boundless Bio, Inc. announced on August 19, 2024, the appointment of Dr. David M. Halbert as Chief Medical Officer and the election of Ms. Sarah E. Kelly to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are filed as an exhibit.

Why It Matters

These executive and board changes can signal shifts in the company's strategic direction and leadership, potentially impacting its future development and operational focus.

Risk Assessment

Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer of Boundless Bio?

Dr. David M. Halbert has been appointed as the new Chief Medical Officer of Boundless Bio.

Who has been elected to the Board of Directors of Boundless Bio?

Ms. Sarah E. Kelly has been elected to the Board of Directors of Boundless Bio.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is August 19, 2024.

What is the principal executive office address for Boundless Bio?

The address of the Principal Executive Offices is 9880 Campus Point Drive, Suite 120, San Diego, California 92121.

What other information is Boundless Bio filing regarding its officers?

Boundless Bio is filing information regarding compensatory arrangements of certain officers.

Filing Stats: 751 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-08-20 17:00:22

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BOUNDLESS BIO, INC. Date: August 20, 2024 By: /s/ Jessica Oien Name: Jessica Oien Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing